No­vo Nordisk's GLP-1 for Type II di­a­betes ap­proved for first-line treat­ment

Ry­bel­sus, No­vo Nordisk’s GLP-1 al­so known as semaglu­tide, snagged a la­bel up­date from the FDA, al­low­ing pa­tients to take it as a first-line treat­ment for Type II di­a­betes in 7 or 14 mg, the com­pa­ny an­nounced.

The up­date came af­ter its ini­tial ap­proval in 2019, when the drug hit the mar­ket as the first GLP-1 pill to en­ter the Type II di­a­betes mar­ket. And it re­mains the on­ly one. It’s an ana­log of the hor­mone glucagon-like pep­tide-1 (GLP-1).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER